> Details

Hayward, Kelly L.; McKillen, Benjamin J.; Horsfall, Leigh U.; McIvor, Carolyn; Liew, Katerina; Sexton, Jo; Johnson, Amy L.; Irvine, Katharine M.; Valery, Patricia C.; McPhail, Steven M.; Britton, Laurence J.; Rosenberg, William; Weate, Ingrid; Williams, Sue; Powell, Elizabeth E.

Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care
  • Contributor: Hayward, Kelly L.; McKillen, Benjamin J.; Horsfall, Leigh U.; McIvor, Carolyn; Liew, Katerina; Sexton, Jo; Johnson, Amy L.; Irvine, Katharine M.; Valery, Patricia C.; McPhail, Steven M.; Britton, Laurence J.; Rosenberg, William; Weate, Ingrid; Williams, Sue; Powell, Elizabeth E.
  • imprint: Wiley, 2022
  • Published in: Internal Medicine Journal
  • Language: English
  • DOI: 10.1111/imj.15422
  • ISSN: 1444-0903; 1445-5994
  • Keywords: Internal Medicine
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The optimal strategy to support primary care practitioners (PCP) to assess fibrosis severity in non‐alcoholic fatty liver disease (NAFLD) and thereby make appropriate management decisions remains unclear.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>To examine the feasibility of using a two‐step pathway that combined simple scores (NAFLD Fibrosis Score and Fibrosis‐4 Index) with transient elastography (FibroScan) to streamline NAFLD referrals from a ‘routine’ primary care population to specialist hepatology management clinics (HMC).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The two‐step ‘Towards Collaborative Management of NAFLD’ (TCM‐NAFLD) fibrosis risk assessment pathway was implemented at two outer metropolitan primary healthcare practices in Brisbane. Patients aged ≥18 years with a new or established PCP‐diagnosis of NAFLD were eligible for assessment. The pathway triaged patients at ‘high risk’ of clinically significant fibrosis to HMC for specialist review, and ‘low risk’ patients to receive ongoing management and longitudinal follow up in primary care.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 162 patient assessments between June 2019 and December 2020 were included. Mean age was 58.7 ± 11.7 years, 30.9% were male, 54.3% had type 2 diabetes or impaired fasting glucose, and mean body mass index was 34.2 ± 6.9 kg/m<jats:sup>2</jats:sup>. A total 122 patients was considered ‘low risk’ for clinically significant fibrosis, two patients had incomplete assessments and 38 (23.5%) were triaged to HMC. Among 31 completed HMC assessments to date, 45.2% were considered to have clinically significant (or more advanced) fibrosis, representing 9.2% of 153 completed assessments.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Implementation of the two‐step TCM‐NAFLD pathway streamlined hepatology referrals for NAFLD and may facilitate a more cost‐effective and targeted use of specialist hepatology resources.</jats:p></jats:sec>